Anticancer Activity of the Marine Triterpene Glycoside Cucumarioside A<sub>2</sub>-2 in Human Prostate Cancer Cells
2023
Ekaterina S. Menchinskaya | Sergey A. Dyshlovoy | Simone Venz | Christine Jacobsen | Jessica Hauschild | Tina Rohlfing | Aleksandra S. Silchenko | Sergey A. Avilov | Stefan Balabanov | Carsten Bokemeyer | Dmitry L. Aminin | Gunhild von Amsberg | Friedemann Honecker
Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (CRPC), treatment is inevitably hampered by the development of drug resistance. Thus, new drugs are urgently needed. We investigated the efficacy, toxicity, and mechanism of action of the marine triterpene glycoside cucumarioside A<sub>2</sub>-2 (CA<sub>2</sub>-2) using an in vitro CRPC model. CA<sub>2</sub>-2 induced a G<sub>2</sub>/M-phase cell cycle arrest in human prostate cancer PC-3 cells and caspase-dependent apoptosis executed via an intrinsic pathway. Additionally, the drug inhibited the formation and growth of CRPC cell colonies at low micromolar concentrations. A global proteome analysis performed using the 2D-PAGE technique, followed by MALDI-MS and bioinformatical evaluation, revealed alterations in the proteins involved in cellular processes such as metastatic potential, invasion, and apoptosis. Among others, the regulation of keratin 81, CrkII, IL-1β, and cathepsin B could be identified by our proteomics approach. The effects were validated on the protein level by a 2D Western blotting analysis. Our results demonstrate the promising anticancer activity of CA<sub>2</sub>-2 in a prostate cancer model and provide insights on the underlying mode of action.
显示更多 [+] 显示较少 [-]